Figures & data
Table 1 Demographics and Outcomes of All Intensive Care Unit Patients Receiving CAS, VOR or the Combination Therapy for Invasive Fungal Infectionsa
Table 2 Demographics and Outcomes of Intensive Care Unit Patients Receiving Empirical or Preemptive Therapy of CAS, VOR or the Combination for Invasive Fungal Infectionsa
Table 3 Demographics and Outcomes of Intensive Care Unit Patients Receiving Targeted Therapy of CAS, VOR or the Combination for Invasive Fungal Infectionsa
Table 4 Demographics and Outcomes of All Intensive Care Unit Patients Receiving CAS, L-AmB or the Combination Therapy for Invasive Fungal Infectionsa
Table 5 Demographics and Outcomes of Intensive Care Unit Patients Receiving Empirical and Preemptive Therapy of CAS, L-AmB or the Combination for Invasive Fungal Infectionsa
Table 6 Demographics and Outcomes of Intensive Care Unit Patients Receiving Targeted Therapy of CAS, L-AmB or the Combination for Invasive Fungal Infectionsa
Figure 1 Composition flowchart of ICUs. ICUs: intensive-care units; CAS, caspofungin; VOR, voriconazole; L-AmB, amphotericin B liposome. The bold texts represent the number of patients receiving empirical therapy, preemptive therapy and targeted therapy of CAS, VOR, CAS+VOR, L-AmB and CAS+L-AmB, respectively.
![Figure 1 Composition flowchart of ICUs. ICUs: intensive-care units; CAS, caspofungin; VOR, voriconazole; L-AmB, amphotericin B liposome. The bold texts represent the number of patients receiving empirical therapy, preemptive therapy and targeted therapy of CAS, VOR, CAS+VOR, L-AmB and CAS+L-AmB, respectively.](/cms/asset/3474f888-c02f-4d42-8fc1-a8b65b064d41/didr_a_381851_f0001_c.jpg)